Biomarkers in medicine最新文献_第2页

KLK8: charting new territories in left ventricular hypertrophy biomarker research. KLK8：左心室肥厚生物标志物研究的新领域。

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-04-01 Epub Date: 2025-04-02 DOI: 10.1080/17520363.2025.2483153

Buqing Cao, Wenhong Yu, Zhihong Diao, Zhenli Ma, Shineng Yan, Lihua Yang, Xiaoqun Huang, Jingmei Yang

{"title":"KLK8: charting new territories in left ventricular hypertrophy biomarker research.","authors":"Buqing Cao, Wenhong Yu, Zhihong Diao, Zhenli Ma, Shineng Yan, Lihua Yang, Xiaoqun Huang, Jingmei Yang","doi":"10.1080/17520363.2025.2483153","DOIUrl":"10.1080/17520363.2025.2483153","url":null,"abstract":"Objective: This study investigates the diagnostic potential of serum Kallikrein-related peptidase 8 (KLK8) in detecting left ventricular hypertrophy (LVH).Methods: A total of 62 hypertensive patients with LVH, 60 without LVH, and 60 healthy controls were analyzed. LVH was defined by echocardiography using LVMI thresholds (>95 g/m2 for females, >115 g/m2 for males). Serum KLK8 levels were measured via ELISA, and receiver operating characteristic (ROC) curve analysis assessed its diagnostic performance.Results: KLK8 levels were significantly higher in hypertensive patients with LVH (8.59 ± 1.59 ng/mL) than in those without LVH (5.80 ± 1.35 ng/mL) and healthy controls (3.68 ± 0.82 ng/mL). KLK8 positively correlated with blood pressure and cardiac structural parameters, including IVST, LVPWT, and LVEDD. ROC analysis revealed high sensitivity and specificity, indicating KLK8's potential as a biomarker for early LVH detection in hypertension.Conclusion: In hypertensive patients, KLK8 demonstrates good diagnostic value in predicting LVH.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"277-286"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive power of ALBI score-based nomogram for 30-day mortality following transcatheter aortic valve implantation.

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-30 DOI: 10.1080/17520363.2025.2483157

Abdullah Yildirim, Omer Genc, Mert Evlice, Aslan Erdogan, Emre Pacaci, Ahmet Ozderya, Murat Gokhan Yerlikaya, Emre Sezici, Yeliz Guler, Omer Sen, Ahmet Guler, Ali Riza Akyuz, Levent Korkmaz, Ibrahim Halil Kurt

{"title":"Predictive power of ALBI score-based nomogram for 30-day mortality following transcatheter aortic valve implantation.","authors":"Abdullah Yildirim, Omer Genc, Mert Evlice, Aslan Erdogan, Emre Pacaci, Ahmet Ozderya, Murat Gokhan Yerlikaya, Emre Sezici, Yeliz Guler, Omer Sen, Ahmet Guler, Ali Riza Akyuz, Levent Korkmaz, Ibrahim Halil Kurt","doi":"10.1080/17520363.2025.2483157","DOIUrl":"https://doi.org/10.1080/17520363.2025.2483157","url":null,"abstract":"Aim: This retrospective, multi-center study evaluates the relationships between novel liver function scoring systems - Albumin-Bilirubin (ALBI) score, EZ-ALBI, PALBI, and MELD-XI - and outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). Feature importance was assessed with SHAP-values via the XGBoost-algorithm.Results: The ALBI score exhibited the strongest association with 30-day mortality after TAVI (AUC = 0.723, p < 0.001), outperforming other scores in this regard and consistently demonstrating predictive power across various subgroup populations. Higher 30-day mortality rates were observed in the higher tertiles of the ALBI score compared to the lower tertiles (log-rank p-value = 0.004). The ALBI-based nomogram (C-index = 0.81, 95% CI:0.73-0.86, p = 0 < 001) demonstrated superior predictive power for 30-day mortality post-TAVI compared to the STS (C-index = 0.71, 95% CI :0.64-0.77, p = 0 < 001). In addition, the nomogram showed a significant improvement in reclassification (69.3%, p < 0.001) and a stronger discrimination 15.2%, p < 0.001) compared to the STS. It integrates nine variables, first ALBI score (SHAP:1.165), including NYHA class (0.594), body mass index (0.510), glomerular filtration rate, creatinine, hemoglobin, gender, predilatation requirement, presence of chronic kidney disease, and providing a comprehensive risk assessment tool.Conclusion: This study exhibits the significance of liver dysfunction with AS patients and suggests incorporating liver function parameters in pre-operative risk assessments for better clinical outcomes in TAVI procedures.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

5-Hydroxymethylcytosine signatures in circulating cell-free DNA as potential diagnostic markers for breast cancer.

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-26 DOI: 10.1080/17520363.2025.2483156

Nadire Aishan, Siwei Ju, Zhongqiu Zheng, Yongxia Chen, Qingna Meng, Qina He, Jiahang Zhang, Jiaheng Lang, Bojian Xie, Lidan Jin, Jun Shen, Yi Lu, Yangjun Cai, Feiyang Ji, Feilin Cao, Linbo Wang

{"title":"5-Hydroxymethylcytosine signatures in circulating cell-free DNA as potential diagnostic markers for breast cancer.","authors":"Nadire Aishan, Siwei Ju, Zhongqiu Zheng, Yongxia Chen, Qingna Meng, Qina He, Jiahang Zhang, Jiaheng Lang, Bojian Xie, Lidan Jin, Jun Shen, Yi Lu, Yangjun Cai, Feiyang Ji, Feilin Cao, Linbo Wang","doi":"10.1080/17520363.2025.2483156","DOIUrl":"https://doi.org/10.1080/17520363.2025.2483156","url":null,"abstract":"Aims: Breast cancer is one of the most prevalent cancers among women, and early diagnosis is crucial in reducing the mortality rate. This study aims to identify novel, reliable, and specific biomarkers for breast cancer diagnosis using 5-Hydroxymethylcytosine (5hmC) signatures in circulating cell-free DNA (cfDNA).Materials and methods: We utilized the sensitive 5hmC seal method to map 5hmC profiles in cfDNA samples from 203 breast cancer patients and 60 healthy individuals. Machine learning models were applied to identify 5hmC marker signatures with high sensitivity and specificity.Results: A global loss of 5hmC was observed in the blood samples from cancer patients compared to the control group. Several specific 5hmC marker signatures were identified, providing a basis for distinguishing between tumor and healthy individuals.Conclusions: Our study offers a comprehensive understanding of genome-wide 5hmC in cfDNA from breast cancer patients, and identifies valuable epigenetic biomarkers for the minimally invasive diagnosis of breast cancer.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment. 血液恶性肿瘤的综合生物标志物图谱：改善诊断、预后和治疗。

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-01 Epub Date: 2025-02-27 DOI: 10.1080/17520363.2025.2471745

Ali Golestan, Mohammadrasul Zareinejad, Amin Ramezani

{"title":"Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment.","authors":"Ali Golestan, Mohammadrasul Zareinejad, Amin Ramezani","doi":"10.1080/17520363.2025.2471745","DOIUrl":"10.1080/17520363.2025.2471745","url":null,"abstract":"Hematological malignancies present substantial challenges in clinical practice due to their heterogeneity and complex biological profiles. In these diseases, biomarkers - measurable indicators of biological states - are indispensable for diagnosis, prognosis, and therapeutic decision-making. Emerging biomarkers are significantly improving outcomes in hematological cancers by enhancing early detection, refining prognostic assessments, enabling personalized treatment approaches, and optimizing overall patient management. This progress translates into better clinical outcomes and more effective strategies to treat and manage malignancies. The field of biomarker discovery has developed from basic morphological and cytogenetic markers to advanced molecular techniques, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), which have significantly enhanced diagnostic accuracy and led to the development of targeted therapies. Additionally, the recent advent of technologies like mass spectrometry and single-cell RNA sequencing enables comprehensive molecular profiling and reveals novel biomarkers that were previously undetectable. Our aim in this manuscript is to provide a comprehensive overview of recent and novel immunohematological biomarkers, their diagnostic and therapeutic applications, and the future directions of this field.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"223-238"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel inflammatory biomarkers for discriminating vascular involvement in Behçet's syndrome: evaluating SII, SIRI, and NPAR.

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-01 Epub Date: 2025-03-02 DOI: 10.1080/17520363.2025.2473312

Bahar Özdemir Ulusoy, Berkan Armağan, Esra Kayacan Erdoğan, Yüksel Maraş, İsmail Doğan, Kevser Orhan, Serdar Can Güven, Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Ahmet Omma, Orhan Küçükşahin, Şükran Erten, Hakan Babaoğlu

{"title":"Novel inflammatory biomarkers for discriminating vascular involvement in Behçet's syndrome: evaluating SII, SIRI, and NPAR.","authors":"Bahar Özdemir Ulusoy, Berkan Armağan, Esra Kayacan Erdoğan, Yüksel Maraş, İsmail Doğan, Kevser Orhan, Serdar Can Güven, Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Ahmet Omma, Orhan Küçükşahin, Şükran Erten, Hakan Babaoğlu","doi":"10.1080/17520363.2025.2473312","DOIUrl":"10.1080/17520363.2025.2473312","url":null,"abstract":"Objective: This study aims to investigate discriminatory ability of the Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Neutrophil Percentage-to-Albumin Ratio (NPAR), in differentiating Behçet's Syndrome (BS) organ involvements from mucocutaneous involvement.Methods: This retrospective cohort study analyzed 436 patients diagnosed with BS from 2018 to 2023. Patients were categorized into three groups based on organ involvement: vascular, only mucocutaneous, and other organ involvement. Receiver Operating Characteristic (ROC) analysis was used to evaluate the discriminatory ability (mucocutaneous vs rest, vascular vs rest). DeLong's test was used to determine statistical differences in discriminatory power between the models.Results: Out of 436, 115 patients had vascular involvement. SII, SIRI, and NPAR were notably elevated in the vascular involvement group (p < 0.001). ROC analysis revealed that, SII, SIRI and NPAR showed discriminative ability for vascular involvement with AUCs of 0.87 for SII, 0.87 for SIRI, and 0.88 for NPAR. Pairwise comparisons using DeLong's test indicated that all three models performed similarly.Conclusion: SII, SIRI, and NPAR are promising noninvasive biomarkers for predicting vascular involvement. These indices, derived from routine laboratory tests, could enhance early screening and may improve patient outcomes by enabling timely intervention.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"149-156"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic role of circulating cell-free DNA in schizophrenia and neuro-degenerative disorders.

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-01 Epub Date: 2025-02-24 DOI: 10.1080/17520363.2025.2468151

Miltiadis Perdikakis, Dimosthenis Papadimitrakis, Nikitas Floros, Elias Tzavellas, Christina Piperi, Antonios N Gargalionis, Athanasios G Papavassiliou

{"title":"Diagnostic role of circulating cell-free DNA in schizophrenia and neuro-degenerative disorders.","authors":"Miltiadis Perdikakis, Dimosthenis Papadimitrakis, Nikitas Floros, Elias Tzavellas, Christina Piperi, Antonios N Gargalionis, Athanasios G Papavassiliou","doi":"10.1080/17520363.2025.2468151","DOIUrl":"10.1080/17520363.2025.2468151","url":null,"abstract":"Over the past few years, circulating cell-free DNA (cfDNA) research has grown exponentially. Several studies have associated the release of cfDNA in the bloodstream, cerebrospinal fluid, and other body fluids with increased apoptosis and cell death. Therefore, their possible use as biomarkers for cancer and other diseases has emerged. The diagnosis of pathological entities such as schizophrenia and neurodegenerative diseases involves many challenges and requires ruling out conditions with similar symptoms. In this context, cfDNA could serve as a valuable diagnostic biomarker. This study encompasses the recent bibliography and research regarding the utilization of circulating cfDNA for diagnostic purposes in schizophrenia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. This minimally invasive method has provided important evidence regarding the diagnosis of the aforementioned diseases although further research is necessary.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"165-176"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of HALP score in predicting in-hospital mortality in patients with NSTEMI.

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-01 Epub Date: 2025-02-26 DOI: 10.1080/17520363.2025.2468144

Dogan Ilis, Ayca Arslan, Inanc Artac, Muammer Karakayali, Timor Omar, Serif Hamideyin, Hatice Taşkan, Ozcan Yagicibulut, Yavuz Karabag, Ibrahim Rencuzogullari

{"title":"Prognostic value of HALP score in predicting in-hospital mortality in patients with NSTEMI.","authors":"Dogan Ilis, Ayca Arslan, Inanc Artac, Muammer Karakayali, Timor Omar, Serif Hamideyin, Hatice Taşkan, Ozcan Yagicibulut, Yavuz Karabag, Ibrahim Rencuzogullari","doi":"10.1080/17520363.2025.2468144","DOIUrl":"10.1080/17520363.2025.2468144","url":null,"abstract":"Aims: We aimed to investigate the association between the HALP score and in-hospital mortality in patients with non-ST segment myocardial infarction (NSTEMI).Materials and methods: In this retrospective study participants were divided into two groups, based on the median HALP score. Findings were compared between the groups.Results: A total of 1648 patients included. The median HALP score cutoff value was 3.87. While the low HALP score group (<3.87) included 824 patients, the high HALP score group (>3.87) included 824 patients. Patients with the low HALP score were older and had a higher prevalence of comorbidities. A HALP score ≤ 2.62 predicted in-hospital mortality with sensitivity of 72.5% and a specificity of 77.3% (area under curve 0.809), according to ROC curve analysis. In multivariate analysis, age, diastolic blood pressure, Killip Class > 1 and Syntax Score, creatinine level, LVEF and HALP Score (OR: 0.504, 95% CI: 0.415-0.613; p < 0.001) were independently associated with in-hospital mortality.Conclusions: According to the current study, the HALP score was independently associated with in-hospital mortality in patients with NSTEMI. Moreover, HALP score might be used as a predictor of in-hospital mortality in this population.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"139-147"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression of MCCC2 in glioma cells and preliminary verification of poor prognosis.

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-01 Epub Date: 2025-03-04 DOI: 10.1080/17520363.2025.2473131

Cheng'ao Feng, Yu Fan, Hongwei Gao, Bowen Zhang, Xiaojie Lu

{"title":"Expression of MCCC2 in glioma cells and preliminary verification of poor prognosis.","authors":"Cheng'ao Feng, Yu Fan, Hongwei Gao, Bowen Zhang, Xiaojie Lu","doi":"10.1080/17520363.2025.2473131","DOIUrl":"10.1080/17520363.2025.2473131","url":null,"abstract":"Aims: This study mainly explored the regulatory role and mechanism of MCCC2 in GBM.Methods: This study verified the expression in clinical samples and GBM cell lines. CCK-8 and cell cloning experiments, flow cytometry, scratch experiments and Transwell chamber experiments were used to detect the effects of MCCC2 expression on proliferation, apoptosis, migration and invasion of GBM cells.Results: A reduction in MCCC2 expression could significantly lower the protein levels of ERK, decrease p-ERK levels, and inhibit ERK phosphorylation. Ulixertinib, an ERK inhibitor, was shown to hinder the proliferation, migration, and invasion of GBM cells and counteract the regulatory impact of MCCC2 overexpression on GBM cells.Conclusions: This investigation revealed that suppressing MCCC2 expression impedes the proliferation, migration, and invasion of GBM cells and promotes GBM cell apoptosis by curtailing ERK expression and phosphorylation. This discovery implies that MCCC2 might serve as a potential biological target for anti-GBM therapy, laying the groundwork for future research in this field.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"205-213"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The relationship between serum Lumican levels and myocardial fibrosis in patients with hypertrophic cardiomyopathy.

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-01 Epub Date: 2025-03-03 DOI: 10.1080/17520363.2025.2473304

Emirhan Hancıoğlu, Sevgi Özcan, Esra Dönmez, Cemal Terzioğlu, Ayşegül Kırankaya, Aslıhan Tenekecigil, Ertugrul Okuyan, İrfan Sahin

{"title":"The relationship between serum Lumican levels and myocardial fibrosis in patients with hypertrophic cardiomyopathy.","authors":"Emirhan Hancıoğlu, Sevgi Özcan, Esra Dönmez, Cemal Terzioğlu, Ayşegül Kırankaya, Aslıhan Tenekecigil, Ertugrul Okuyan, İrfan Sahin","doi":"10.1080/17520363.2025.2473304","DOIUrl":"10.1080/17520363.2025.2473304","url":null,"abstract":"Objective: Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death in young individuals. Lumican, is an indicator of fibrosis. We aimed to evaluate the relation between serum Lumican levels and presence and extent of myocardial fibrosis in HCM.Methods: The patients diagnosed with HCM between June 2022 and March 2023 were enrolled consecutively in this prospective study. Age and gender-matched healthy individuals formed control group. Two groups were generated according to extent of late gadolinium enhancement (LGE) in HCM patients.Results: A total of 114 patients were enrolled. Serum Lumican, NT-proBNP levels and maximum wall thickness were revealed as independent risk factors associated with LGE. A cut-off value of 9.06 for Lumican was associated with 67.8% sensitivity and 65.5% specificity in prediction of LGE.Conclusion: Myocardial fibrosis is one of the important mechanisms in HCM pathophysiology. LGE on cardiac magnetic resonance imaging allows comprehensive evaluation of myocardial fibrosis, the support of diagnosis with a biomarker would be beneficial in clinical practice. Our study revealed that serum Lumican level is an independent predictor of severe LGE in HCM patients. Further studies with larger patient numbers may clarify the importance of Lumican in HCM pathophysiology.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"187-195"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Red cell distribution width related to the severity of the disease in patients with AECOPD.

IF 1.9 4区医学

Biomarkers in medicine Pub Date : 2025-03-01 Epub Date: 2025-03-12 DOI: 10.1080/17520363.2025.2468152

Yiben Huang, Jianing Wang, Siyao Chen, Zicong Dai, Xuanyang Chen, Xinran Li, Ruizi Xu, Beibei Yu, Chunyan Liu, Xianjing Chen, Pengfei Zhang, Yage Xu, Xiaodiao Zhang

{"title":"Red cell distribution width related to the severity of the disease in patients with AECOPD.","authors":"Yiben Huang, Jianing Wang, Siyao Chen, Zicong Dai, Xuanyang Chen, Xinran Li, Ruizi Xu, Beibei Yu, Chunyan Liu, Xianjing Chen, Pengfei Zhang, Yage Xu, Xiaodiao Zhang","doi":"10.1080/17520363.2025.2468152","DOIUrl":"10.1080/17520363.2025.2468152","url":null,"abstract":"Aims: This research aims to elucidate the association between red cell distribution width (RDW) and the severity of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).Patients & methods: This retrospective study enrolled patients with AECOPD and healthy controls. A comprehensive meta-analysis was further conducted by systematically searching PubMed, Embase, and the Cochrane Library up to 27 April 2023.Results: Univariate logistic regression analysis indicated that elevated RDW levels were significantly associated with AECOPD (p = 0.016). The pooled results yielded a diagnostic sensitivity of 0.76 (95% CI: 0.70-0.81) and specificity of 0.53 (95% CI: 0.38-0.68) for RDW in predicting AECOPD severity.Conclusion: Elevated RDW levels exhibit a linear positive correlation with AECOPD severity, further supported by meta-analysis.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":"19 5","pages":"177-186"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0